Physician

Adam Wanner, MD

According to 2025 Medicare claims, Adam Wanner, MD (NPI: 1013925684) practices pulmonary disease in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is UNIVERSITY OF MIAMI (NPI: 1003866617; TIN: 592579938) and primary practice location at 33125-1653.

Wanner's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 126 traditional Medicare patients, billed 225 HCPCS/CPT codes, and received $17,764 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 667 prescription claims across 75 beneficiaries totaling $149,085 in drug costs, led by Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter). DME data shows 44 claims. Open Payments data shows 2 records totaling $1,436. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $39,444 to $17,764. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $1,946 and ending at $829.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	202	465	$39,444
2016	210	497	$37,656
2017	194	490	$33,903
2018	225	441	$32,137
2019	228	432	$28,753
2020	227	422	$32,234
2021	228	433	$35,001
2022	225	507	$30,820
2023	208	471	$28,521
2024	126	225	$17,764

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	58	473	$208,471
2016	66	557	$275,327
2017	68	555	$258,782
2018	79	686	$264,118
2019	81	647	$298,148
2020	74	573	$210,145
2021	83	638	$216,897
2022	79	672	$255,040
2023	74	558	$208,218
2024	75	667	$149,085

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	29	$639
2016	N/R	79	$1,923
2017	N/R	43	$1,687
2018	N/R	84	$2,817
2019	N/R	90	$2,833
2020	N/R	134	$12,857
2021	N/R	81	$2,740
2022	N/R	59	$2,089
2023	N/R	25	$454
2024	N/R	44	$999

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	35	51	$107
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	17	18	$105
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	55	111	$64

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	30	1,080	$23,501
Spiriva Handihaler	Tiotropium Bromide	44	1,410	$23,426
Combivent Respimat	Ipratropium/Albuterol Sulfate	13	540	$15,842
Breo Ellipta	Fluticasone/Vilanterol	24	780	$10,570
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	15	450	$9,694

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
Q0513	Pharmacy dispensing fee for inhalation drug(s); per 30 days	N	N/R	17	$414
E1392	Portable oxygen concentrator, rental	Y	N/R	12	$401
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	N	N/R	15	$184

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$1,343	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$93	AstraZeneca Pharmaceuticals LP
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Adam Wanner, MD?

Tedicare shows public-source Medicare data for Adam Wanner, MD (NPI 1013925684), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam Wanner, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Adam Wanner, MD?

Adam Wanner, MD is linked to UNIVERSITY OF MIAMI (billing NPI 1003866617) in the available physician profile data.

Does Adam Wanner, MD have Open Payments data?

Adam Wanner, MD has 2 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.